Suppr超能文献

基于全身照射的清髓性预处理方案在接受异基因造血干细胞移植的急性淋巴细胞白血病患者中的影响:系统评价和荟萃分析。

Impact of Total Body Irradiation-Based Myeloablative Conditioning Regimens in Patients with Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: Systematic Review and Meta-Analysis.

机构信息

Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida.

Morsani College of Medicine, University of South Florida, Tampa, Florida.

出版信息

Transplant Cell Ther. 2021 Jul;27(7):620.e1-620.e9. doi: 10.1016/j.jtct.2021.03.026. Epub 2021 Mar 30.

Abstract

Allogeneic hematopoietic cell transplantation (allo-HCT) is a curative treatment option for patients with acute lymphoblastic leukemia (ALL). Both total body irradiation (TBI)-based and chemotherapy only-based myeloablative transplantation conditioning regimens have been applied, but the optimal regimen remains unclear. We performed a systematic review to assess the efficacy of TBI-based versus chemotherapy only-based myeloablative conditioning regimens. We searched PubMed, Embase, and Cochrane databases and meeting abstracts for all studies comparing TBI-based and chemotherapy only-based conditioning regimens in patients who underwent allo-HCT for ALL. Two authors independently reviewed all studies for inclusion and extracted data related to overall survival (OS), progression-free survival (PFS), nonrelapse mortality (NRM), relapse, and acute and chronic graft-versus-host disease (GVHD). Eight studies were included in the final analysis. The overall methodological quality of the included studies was optimal. TBI-based regimens showed evidence of benefit compared with chemotherapy only-based conditioning regimens in terms of relapse (relative risk [RR], 0.82; 95% confidence interval [CI], 0.72 to 0.94; 6 studies, 5091 patients), OS (hazard ratio [HR], 0.76; 95% CI, 0.64 to 0.89; 7 studies, 4727 patients), and PFS (HR, 0.74; 95% CI, 0.63 to 0.85; 7 studies, 4727 patients). The TBI-based regimen did not increase the likelihood of grade II-IV acute GVHD (RR, 1.12; 95% CI, 0.92 to 1.36; 5 studies, 4996 patients) or chronic GVHD (RR, 1.10; 95% CI, 1.00 to 1.21; 5 studies, 4490 patients), or NRM (RR, 0.94; 95% CI, 0.69 to 1.28; 6 studies, 4522 patients). However, TBI-based regimens were associated with an increased risk of grade III-IV acute GVHD (RR, 1.29; 95% CI, 1.01 to 1.63; 3 studies, 3675 patients). A subgroup comparison of patients age ≥16 years showed similar results. This systematic review represents evidence supporting the use of TBI-based conditioning regimen in patients undergoing allo-HCT for ALL who are candidates for myeloablative conditioning, as it offers better OS, PFS, and less relapse with acceptable NRM.

摘要

异基因造血细胞移植(allo-HCT)是治疗急性淋巴细胞白血病(ALL)患者的一种有治愈可能的治疗选择。全身体照射(TBI)为基础和以化疗为基础的清髓性移植预处理方案都已得到应用,但最佳方案仍不明确。我们进行了一项系统评价,以评估 TBI 为基础与仅以化疗为基础的清髓性预处理方案的疗效。我们检索了 PubMed、Embase 和 Cochrane 数据库以及会议摘要,以获取所有比较 ALL 患者接受 allo-HCT 时 TBI 为基础与仅以化疗为基础的预处理方案的研究。两名作者独立地对所有研究进行了纳入和提取与总生存(OS)、无进展生存(PFS)、非复发死亡率(NRM)、复发以及急性和慢性移植物抗宿主病(GVHD)相关的数据。最终有 8 项研究纳入了分析。纳入研究的整体方法学质量为最佳。与仅以化疗为基础的预处理方案相比,TBI 为基础的方案在复发(相对风险 [RR],0.82;95%置信区间 [CI],0.72 至 0.94;6 项研究,5091 例患者)、OS(风险比 [HR],0.76;95%CI,0.64 至 0.89;7 项研究,4727 例患者)和 PFS(HR,0.74;95%CI,0.63 至 0.85;7 项研究,4727 例患者)方面显示出获益的证据。TBI 为基础的方案并未增加 2 级至 4 级急性 GVHD(RR,1.12;95%CI,0.92 至 1.36;5 项研究,4996 例患者)或慢性 GVHD(RR,1.10;95%CI,1.00 至 1.21;5 项研究,4490 例患者)或 NRM(RR,0.94;95%CI,0.69 至 1.28;6 项研究,4522 例患者)的发生风险。然而,TBI 为基础的方案与 3 级至 4 级急性 GVHD(RR,1.29;95%CI,1.01 至 1.63;3 项研究,3675 例患者)风险增加相关。对年龄≥16 岁患者的亚组比较得出了相似的结果。这项系统评价提供了支持在 ALL 患者接受 allo-HCT 时使用 TBI 为基础的预处理方案的证据,这些患者适合接受清髓性预处理,因为它可提供更好的 OS、PFS 和更少的复发,同时 NRM 可接受。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验